Outcome document for Joint Scientific Consultations (JSC) on Medicinal Products (MP)
The Outcome document for Joint Scientific Consultations on Medicinal Products has been adopted on 28 November 2024 by the HTACG pursuant to Article 3(7), point (d), of Regulation (EU) 2021/2282 on Health Technology Assessment.
According to recital 39 of Regulation (EU) 2021/2282, “any guidance offered should not be legally binding either on the health technology developers or on HTA authorities and bodies. Such guidance, however, should reflect the state of the art of medical science at the time of the joint scientific consultation, in particular in the interest of patients.”
Read the background document published by Directorate-General for Health and Food Safety on 28 November 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (12 janvier 2025). Outcome document for Joint Scientific Consultations (JSC) on Medicinal Products (MP). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/132dm





